Publication:
In vivo protective effect of Uridine, a pyrimidine nucleoside, on genotoxicity induced by Levodopa/Carbidopa in mice

dc.contributor.authorYaylagül, Esra Örenlili
dc.contributor.authorCansev, Mehmet
dc.contributor.authorKasımoğullari, Serap Çelikler
dc.contributor.buuauthorCANSEV, MEHMET
dc.contributor.buuauthorÇELİKLER KASIMOĞULLARI, SERAP
dc.contributor.departmentFen Edebiyat Fakültesi
dc.contributor.departmentFarmakoloji Ana Bilim Dalı
dc.contributor.orcid0000-0003-2918-5064
dc.contributor.researcheridM-9071-2019
dc.contributor.researcheridJCP-8028-2023
dc.date.accessioned2024-08-05T13:06:23Z
dc.date.available2024-08-05T13:06:23Z
dc.date.issued2015-08-01
dc.description.abstractParkinson's disease (PD) is a common neurodegenerative disorder that affects millions of people all over the world. Motor symptoms of PD are most commonly controlled by L-3,4-dihydroxyphenylalanine (Levodopa, L-DOPA), a precursor of dopamine, plus a peripherally-acting aromatic-L-amino-acid decarboxylase (dopa decarboxylase) inhibitor, such as carbidopa. However, chronic treatment with a combination of Levodopa plus carbidopa has been demonstrated to cause a major complication, namely abnormal involuntary movements. On the other hand, the effect of this treatment on bone marrow cells is unknown. Therefore, in this study, we aimed to investigate possible genotoxic effects of Levodopa and Carbidopa using male Balb/C mice. Our results showed that Levodopa alone or in combination with carbidopa caused genotoxicity in in vivo micronucleus test (mouse bone marrow) and Comet assay (blood cells). Furthermore, we showed that simultaneous administration of uridine, a pyrimidine nucleoside, reversed the genotoxic effect of Levodopa and Carbidopa in both assays. Our data show for the first time that Levodopa plus carbidopa combination causes genotoxicity which is reversed by uridine treatment. These findings might enhance our understanding for the complications of a common Parkinson's treatment and confer benefit in terms of reducing a possible genotoxic effect of this treatment.
dc.identifier.doi10.1016/j.fct.2015.05.002
dc.identifier.endpage41
dc.identifier.issn0278-6915
dc.identifier.startpage36
dc.identifier.urihttps://doi.org/10.1016/j.fct.2015.05.002
dc.identifier.urihttps://www.sciencedirect.com/science/article/pii/S0278691515001581
dc.identifier.urihttps://hdl.handle.net/11452/43716
dc.identifier.volume82
dc.identifier.wos000358463200005
dc.indexed.wosWOS.SCI
dc.language.isoen
dc.publisherPergamon-Elsevier
dc.relation.bapUAP(F)- 2010/60
dc.relation.journalFood and Chemical Toxicology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectPlus docosahexaenoic acid
dc.subjectCdp-choline levels
dc.subjectL-dopa
dc.subjectDna-damage
dc.subjectParkinsons-disease
dc.subjectComet assay
dc.subjectPc12 cells
dc.subjectRat model
dc.subjectLevodopa
dc.subject6-hydroxydopamine
dc.subjectLevodopa
dc.subjectCarbidopa
dc.subjectUridine
dc.subjectGenotoxicity
dc.subjectMicronuclei
dc.subjectComet
dc.subjectFood science & technology
dc.subjectToxicology
dc.titleIn vivo protective effect of Uridine, a pyrimidine nucleoside, on genotoxicity induced by Levodopa/Carbidopa in mice
dc.typeArticle
dspace.entity.typePublication
local.contributor.departmentTıp Fakültesi/Farmakoloji Ana Bilim Dalı
local.contributor.departmentFen Edebiyat Fakültesi/Biyoloji Bölümü
relation.isAuthorOfPublication162b5961-162a-4862-89cd-97b30e2a2552
relation.isAuthorOfPublicationd293a689-5b5d-4b75-84b7-ae61987b866a
relation.isAuthorOfPublication.latestForDiscovery162b5961-162a-4862-89cd-97b30e2a2552

Files

Collections